RxDoctor Payments Data

David Grogan

Physician Assistant · Warner Robins, GANPI 1841294386

Payments from drug & device makers

$1,575in general payments, 2019–2025

Across 58 payments — averaging $27.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$370
  • Bausch & Lomb Americas Inc.$303
  • Harrow Eye, LLC$185
  • Sun Pharmaceutical Industries Inc.$154
  • Tarsus Pharmaceuticals, Inc.$106
  • Alcon$101
  • plus $356 from 8 others

What the payments were for

  • Food & beverage$1,575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,575 in reported general payments places this provider in the 75th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$11,633
Medicare patients
124
Services billed
201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost253$125,492
RestasisCyclosporine69$77,566
XiidraLifitegrast34$43,440
CombiganBrimonidine Tartrate/Timolol69$23,953
Alphagan PBrimonidine Tartrate77$23,559
IlevroNepafenac54$22,739
Brimonidine Tartrate310$22,303
SimbrinzaBrinzolamide/Brimonidine Tart76$19,626
RocklatanNetarsudil Mesylat/Latanoprost53$19,534
VyzultaLatanoprostene Bunod29$12,533
Cyclosporine22$12,411
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol74$11,779
TyrvayaVarenicline Tartrate13$10,154
Travoprost64$9,384
RhopressaNetarsudil Mesylate14$9,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$370$250,571468 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$303$55,97363 claims
NovartisIlevro$92$22,73954 claims
AlconSimbrinza$101$19,62676 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm$40$19,37191 claims
Oyster Point Pharma, Inc.Tyrvaya$48$10,15413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →